Invivo Therapeutics Holdings Corp. (NVIV)

NASDAQ: NVIV · IEX Real-Time Price · USD
7.61
-0.69 (-8.31%)
At close: Aug 19, 2022 4:00 PM
7.50
-0.11 (-1.45%)
After-hours: Aug 19, 2022 5:25 PM EDT
-8.31%
Market Cap 10.59M
Revenue (ttm) n/a
Net Income (ttm) -10.74M
Shares Out 1.39M
EPS (ttm) -7.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 27,431
Open 8.18
Previous Close 8.30
Day's Range 7.52 - 8.46
52-Week Range 3.50 - 19.25
Beta 1.31
Analysts Buy
Price Target n/a
Earnings Date Aug 19, 2022

About NVIV

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. [Read more...]

Industry Health Care Equipment & Supplies
CEO Richard Toselli
Employees 7
Stock Exchange NASDAQ
Ticker Symbol NVIV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Buy
Stock Forecasts

News

InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the publication of a peer-reviewed manuscript in Neurosurgery describing the previously disclosed 12-...

InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

InVivo Therapeutics Announces Reverse Stock Split

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized co...

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

Other symbols: AVIRHSTONRBOPRVBSYNSQL

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

InVivo Therapeutics Stock Moves Higher On FDA Acceptance Of Preclinical Module For Neuro-Spinal Implant

The FDA has accepted InVivo Therapeutics Holdings Corp's (NASDAQ: NVIV) preclinical module, which is one of three individual modules required for the Company's humanitarian device exemption (HDE) applic...

InVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company's Complete HDE Submission

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtu...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing...

InVivo Therapeutics Announces Closing of $15.0 Million Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 18,750,000 shares of its common stock (or ...

InVivo Therapeutics Announces Presentation at the Upcoming H.C Wainwright Virtual Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp.